1. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
- Author
-
Erkki Soini, Riitta Luosujärvi, C. Asseburg, M. Taiha, Oana Purcaru, Kari Puolakka, HYKS erva, Clinicum, Department of Medicine, Reumatologian yksikkö, and HUS Inflammation Center
- Subjects
Male ,Cost effectiveness ,Cost-Benefit Analysis ,DISEASE-ACTIVITY ,Polyethylene Glycols ,COST-EFFECTIVENESS ,Arthritis, Rheumatoid ,0302 clinical medicine ,Quality of life ,QUALITY-OF-LIFE ,2013 UPDATE ,Pharmacology (medical) ,030212 general & internal medicine ,Certolizumab pegol ,Finland ,Original Research ,Aged, 80 and over ,PRODUCTIVITY COSTS ,Cost–benefit analysis ,General Medicine ,Middle Aged ,3. Good health ,EULAR RECOMMENDATIONS ,Treatment Outcome ,317 Pharmacy ,Antirheumatic Agents ,Rheumatoid arthritis ,Female ,5-YEAR FOLLOW-UP ,Quality-Adjusted Life Years ,BURDEN ,Risk assessment ,medicine.drug ,Health Utilities Index ,Adult ,medicine.medical_specialty ,Risk Assessment ,Health policies ,03 medical and health sciences ,Rheumatology ,Internal medicine ,medicine ,Humans ,REGISTER ,Aged ,030203 arthritis & rheumatology ,business.industry ,medicine.disease ,Quality-adjusted life year ,3121 General medicine, internal medicine and other clinical medicine ,MODIFYING ANTIRHEUMATIC DRUGS ,Physical therapy ,Disease-modifying antirheumatic drugs ,Biological therapies ,Health economics ,business - Abstract
Purpose To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (RA) in Finland. Methods A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015–2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. Results In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7% in 2015 to 5.6% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5%-, 6%-, and 1%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of €7866 per patient, with a more than 95% probability of cost-effectiveness when compared with the current treatment mix. Conclusion The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment for RA patients in Finland. The surplus provided by the CZP risk-sharing scheme could fund treatment for 6% more Finnish RA patients. Funding UCB Pharma. Electronic supplementary material The online version of this article (doi:10.1007/s12325-017-0614-8) contains supplementary material, which is available to authorized users.
- Published
- 2017